Critical review of the management of primary central nervous nongerminomatous germ cell tumors.
Mohammad H Abu ArjaEric BouffetJonathan L FinlayMohamed S AbdelBakiPublished in: Pediatric blood & cancer (2019)
Multimodal strategies have significantly improved the outcomes for patients with central nervous system nongerminomatous germ cell tumors. Two large cooperative group studies have recently reported much improved outcomes compared with historical series. However, a substantial proportion of patients still attain inadequate responses to initial chemotherapy prior to irradiation, with adverse impact upon survival; optimal induction chemotherapy regimens and radiotherapy strategies are as yet unidentified. Outcomes for patients with relapsed disease remain poor. There is an obvious need to incorporate molecular studies within prospective clinical trials that will likely lead to the incorporation of targeted, more effective future treatment strategies.
Keyphrases
- germ cell
- clinical trial
- locally advanced
- end stage renal disease
- early stage
- acute myeloid leukemia
- newly diagnosed
- acute lymphoblastic leukemia
- radiation therapy
- chronic kidney disease
- ejection fraction
- squamous cell carcinoma
- type diabetes
- randomized controlled trial
- prognostic factors
- diffuse large b cell lymphoma
- pain management
- drug delivery
- hodgkin lymphoma
- current status
- drug induced